Thanks Taureanbull. Really appreciate your responses. So in essence , a phase 2 trial for Dementia and/or Parkinsons would have been much bigger in scale/cost than the 4 indications Neuren decided to move forward with, hence the reason it didnt go any further. I am really hoping money was the only reason for not moving forward, as the potential is amazing if the pre-clinicals get an opportunity to be proven (and is proven) via clinical trials.
The first set of phase 2 trial results have a lot hinging on it! Hopefully the Phelan-McDermid results are conclusive enough for all these other possibilities to become very relevant.
- Forums
- ASX - By Stock
- NEU
- Ann: Neuren completes Phelan-McDermid syndrome Phase 2 trial
Ann: Neuren completes Phelan-McDermid syndrome Phase 2 trial, page-37
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$15.48 |
Change
0.000(0.00%) |
Mkt cap ! $1.978B |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 2118 | $17.02 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.94 | 382 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 2118 | 17.020 |
1 | 4835 | 16.500 |
3 | 302 | 16.480 |
2 | 73 | 16.250 |
1 | 408 | 16.200 |
Price($) | Vol. | No. |
---|---|---|
14.710 | 1874 | 3 |
14.830 | 1349 | 1 |
14.980 | 471 | 2 |
15.000 | 1033 | 4 |
15.020 | 1130 | 2 |
Last trade - 10.06am 22/08/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
Day chart unavailable